文献速递艾滋病与性传播感染

依曲韦林与达芦那韦/考比司他联用的药代动力学研究

Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该开放标签固定序列试验在HIV感染者中评估依曲韦林与达芦那韦/考比司他联用的相互影响。依曲韦林使考比司他AUC0-24、Cmax和C24分别降低30%、14%和66%,达芦那韦C24降低56%,而依曲韦林药代动力学不变。治疗耐受良好,HIV-1 RNA均保持检测不到。

要点

  • 依曲韦林显著降低考比司他暴露和达芦那韦谷浓度。
  • 依曲韦林自身药代动力学不受达芦那韦/考比司他影响。
  • 若达芦那韦需与依曲韦林联用,可优先考虑利托那韦增效。

核心结论

  • 依曲韦林与达芦那韦/考比司他联用时考比司他暴露和达芦那韦C24显著下降,依曲韦林药代动力学不变。

研究设计与样本

  • 开放标签固定序列试验,纳入HIV感染者两个队列:达芦那韦/考比司他800/150 mg每日一次队列(n=15)和依曲韦林400 mg每日一次队列(n=15)。

主要发现

  • 依曲韦林联用使考比司他AUC0-24降低30%、Cmax降低14%、C24降低66%。
  • 达芦那韦AUC0-24和Cmax不变,但C24降低56%。
  • 依曲韦林药代动力学参数不受达芦那韦/考比司他影响。
  • 治疗耐受良好,所有参与者HIV-1 RNA保持检测不到。

临床怎么用

  • 若达芦那韦需与依曲韦林联用,临床可优先考虑用利托那韦而非考比司他作为增效剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the effect of etravirine on the pharmacokinetics of darunavir/cobicistat and vice versa. Safety and tolerability of this combination were also evaluated. METHODS: Open-label, fixed-sequence trial in two cohorts of HIV-infected patients on therapy with darunavir/cobicistat 800/150 mg once daily (DRV cohort; n = 15) or etravirine 400 mg once daily (ETR cohort; n = 15). Etravirine or darunavir/cobicistat were added on days 1-14 and 1-7 in participants in the DRV or ETR cohort, respectively. Full pharmacokinetic profiles were obtained on days 0 and 14 in the DRV cohort, and on days 0 and 7 in the ETR cohort. Darunavir, cobicistat and etravirine pharmacokinetic parameters [AUC0-24, Cmax and trough concentrations in plasma (C24)] were calculated for each individual by non-compartmental analysis and were compared using linear mixed-effects models. Adverse events and HIV-1 RNA in plasma were monitored. RESULTS: Etravirine co-administration decreased cobicistat AUC0-24, Cmax and C24 by 30%, 14% and 66%, respectively. Although darunavir AUC0-24 and Cmax were unchanged by etravirine, darunavir C24 was 56% lower for darunavir/cobicistat co-administered with etravirine relative to darunavir/cobicistat alone. Etravirine pharmacokinetics were unchanged by darunavir/cobicistat. Treatments were well tolerated, and HIV-1 RNA remained undetectable in all participants. CONCLUSIONS: Although etravirine pharmacokinetics was unchanged by darunavir/cobicistat, there was a significant decrease in cobicistat exposure and in darunavir C24 when darunavir/cobicistat was co-administered with etravirine. Boosting darunavir with ritonavir instead of with cobicistat may be preferred if darunavir is to be combined with etravirine in clinical practice.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Moltó J, Curran A, Miranda C, et al. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. J Antimicrob Chemother. 2018. PMID: 29237008. doi:10.1093/jac/dkx459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。